Inferra AIResearch Tools

Inferra AI / Company / ONC

BeOne Medicines

ONC · Health Care

Last earnings Aug 5, 2026

Key results

Revenuequarter

$1.7 billion

revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Product revenuequarter

$1.7 billion

Exhibit 99.1 Second Quarter 2026 Financial Results Product Revenue totaled $1.7 billion for the second quarter of 2026, representing growth of 29% compared to the prior-year period.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Gross Margin as a percentage of global product sales for the second quarter of 2026 was 90%, compared to 87% in the prior-year period on a GAAP basis.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Per Share GAAP net incomequarter

$237 million

Net Income and Basic Diluted Earnings Per Share GAAP net income for the second quarter of 2026 was $237 million, an increase of $143 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Adjusted net incomequarter

$444 million

Adjusted net income was $444 million, an increase of $192 million over the prior-year period.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Free cash flowquarter

$435 million

Exhibit 99.1 Free Cash Flow for the second quarter of 2026 was $435 million, representing an increase of $216 million over the prior-year period.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

AI analysis

Q2 2026 · reported Aug 5, 2026

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q2 2026
$1.7B
EX-99 · Aug 5, 2026
Free cash flow · Q2 2026
$435M
EX-99 · Aug 5, 2026
Adjusted net income · Q2 2026
$444M
EX-99 · Aug 5, 2026
Product revenue · Q2 2026
$1.7B
EX-99 · Aug 5, 2026

Headline figures

MetricQ2 2026Prior qtrYear ago
Revenue$1.7 billion——
Product revenue$1.7 billion——
Per Share GAAP net income$237 million——
Adjusted net income$444 million——
Free cash flow$435 million——

EX-99 · Aug 5, 2026

Guidance · company-stated

Gross margin

“percentage is expected to be in the high-80%”

net income

“and earnings per ADS Other income (expense) Estimated range of $25 million to $50 million”

Guidance stated in the release's Business Outlook table for full year 2026; no direction stated — figures as stated in the table.

Next earningsNo verified date on fileNo date is estimated or imported

Cash flow & capex

Free cash flow$435M
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Oyler, Co-Founder, Chairman, and CEO, BeOne, said These strong second-quarter results underscore our continued growth as a global oncology leader

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Gross margin: “Gross margin percentage is expected to be in the high-80%”

net income: “net income and earnings per ADS Other income (expense) Estimated range of $25 million to $50 million”

Gross margin (“full year 2026”)
“Gross margin percentage is expected to be in the high-80%”

net income (“full year 2026”)
“net income and earnings per ADS Other income (expense) Estimated range of $25 million to $50 million”

Guidance stated in the release's Business Outlook table for full year 2026; no direction stated — figures as stated in the table.

Strategy & priorities

and continued global expansion in both Europe and other important rest of world markets.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Exhibit 99.1 Corporate Updates Announced a $300 million expansion of the Company s flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, to add small molecule manufacturing capabilities.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne s continued growth as a global oncology leader BeOne s pipeline catalysts BeOne s full year 2026 guidance BeOne s expectations regarding continued global expansion and investment to support growth upcoming R D milestones to be achieved by BeOne the timing of clinical and regulatory developments and data readouts and BeOne s plans, commitments, aspirations and goals under the caption About BeOne.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Risks & headwinds

See Form 10-Q for additional updates on income tax uncertainties.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Securities and Exchange Commission ( SEC ), as well as discussions of potential risks, uncertainties, and other important factors in BeOne s subsequent filings with the SEC.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

BeOne s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

SEC original ↗BeOne Medicines — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Documents

Earnings deck slides

0 decks with slide view

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

BeOne Medicines — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

63 documents

Earnings releases

8 documents

Presentations

8 documents

Transcripts

0 documents

No transcripts for BeOne Medicines are held in this edition of the library.

Mentioned by

3 companies

Other tracked companies whose held documents mention BeOne Medicines by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.